CorMedix Stock Jumps on Strong DefenCath Sales - Cormedix (NASDAQ:CRMD)

CorMedix Q2 earnings beat estimates as sales more than doubled, DefenCath revenue grew, and the company reaffirmed 2026 sales guidance.

Raccontata dabenzinga.com